• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Appoints Dayton Judd to the Board of Directors

    2/15/24 4:05:00 PM ET
    $FTLF
    $LFVN
    $OPXS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FTLF alert in real time by email

    SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these discussions, the Company and the Radoff-Sudbury Group worked together to create a framework for long-term collaboration between the parties. The appointment of Dayton Judd to the Board is in connection with a Cooperation Agreement entered into between the Company and the Radoff-Sudbury Group.

    Steve Fife, LifeVantage's President and Chief Executive Officer, commented, "We welcome Dayton to the Board and believe his insights and perspective will benefit the Company and its shareholders. The LV360 initiatives are driving improving profitability and we remain on track to return Adjusted EBITDA margins back to double-digit levels. Coupled with our strong balance sheet, we expect to continue returning a meaningful portion of excess free cash flow to shareholders through dividends and share repurchases."  

    "I'm thrilled to join the Board and look forward to working closely with my fellow directors and the management team as we continue focusing on driving value for all shareholders," said Dayton Judd. "With its unique assortment of high-quality, innovative products and a powerful business model, LifeVantage is well positioned for growth, improved profitability and higher returns on capital."

    "Dayton is an accomplished executive with a strong track record in, and deep understanding of, the health and wellness industry," said Ray Greer, Chairman. "The combination of his financial and industry expertise is a great addition to the Board. We appreciate our engagement with the Radoff-Sudbury Group and are mutually aligned on the pathway to maximizing value for all shareholders."

    The Radoff-Sudbury Group has agreed to abide by certain customary standstill, voting commitment and other provisions in connection with the Cooperation Agreement. The full agreement between the Company and the Radoff-Sudbury Group will be filed on a Form 8-K with the U.S. Securities and Exchange Commission ("SEC").

    Dayton Judd Biography

    Dayton Judd has served as the Chief Executive Officer of FitLife Brands, Inc. (NASDAQ:FTLF) ("FitLife"), a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers, since February 2018, and founder and Managing Member of Sudbury Capital Management, LLC, a provider of investment advisory services, since 2012. Prior to that, he served as a Portfolio Manager for Q Investments, L.P., a multi-billion-dollar hedge fund, from 2007 through 2011, and held various positions at McKinsey & Company, Inc., a global management consulting firm, from 1996 to 1998 and again from 2000 to 2007. Mr. Judd currently serves as Chairman of FitLife, where he has served as a director since 2017, and has also served as a director of Optex Systems Holdings, Inc. (NASDAQ:OPXS), a manufacturer of optical sighting systems and assemblies, since October 2022, where he also serves as Audit Committee Chair. Mr. Judd is a Certified Public Accountant. He received an M.B.A. with high distinction from Harvard Business School, where he was a Baker Scholar, and earned his M.S. and B.S., summa cum laude, in Accounting from Brigham Young University.

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN), the activation company, is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company's line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, the TrueScience® line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio®, its nootropic energy drink mixes, and PhysIQ, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

    Cautionary Note Regarding Forward Looking Statements

    This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," "may be," and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, the impact of COVID-19 on our business, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Reports on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]



    Primary Logo

    Get the next $FTLF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTLF
    $LFVN
    $OPXS

    CompanyDatePrice TargetRatingAnalyst
    FitLife Brands Inc.
    $FTLF
    3/17/2025$21.00Buy
    Lake Street
    Lifevantage Corporation
    $LFVN
    1/14/2025$35.00Buy
    Craig Hallum
    Lifevantage Corporation
    $LFVN
    12/19/2024$26.00Buy
    Lake Street
    FitLife Brands Inc.
    $FTLF
    9/3/2024$40.00Buy
    ROTH MKM
    More analyst ratings

    $FTLF
    $LFVN
    $OPXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on FitLife Brands with a new price target

    Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

    3/17/25 8:22:47 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FTLF
    $LFVN
    $OPXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anbalagan Rajendran was granted 13,531 shares, increasing direct ownership by 129% to 23,999 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Latham Cynthia was granted 13,531 shares, increasing direct ownership by 26% to 64,879 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:15:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Greer Raymond B was granted 13,531 shares, increasing direct ownership by 14% to 112,819 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    11/10/25 7:14:59 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FTLF
    $LFVN
    $OPXS
    SEC Filings

    View All

    FitLife Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

    11/13/25 7:45:16 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by FitLife Brands Inc.

    10-Q - FITLIFE BRANDS, INC. (0001374328) (Filer)

    11/13/25 7:30:53 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Lifevantage Corp (0000849146) (Filer)

    11/12/25 4:35:42 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FTLF
    $LFVN
    $OPXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $4,882 worth of shares (450 units at $10.85), increasing direct ownership by 0.39% to 117,217 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/18/25 4:36:17 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    6/17/25 4:11:27 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    5/13/25 4:11:14 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FTLF
    $LFVN
    $OPXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FitLife Brands Announces Third Quarter 2025 Results

    OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include: On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals ("Irwin"), and Irwin's operating results for the period of August 9 through September 30 are included in FitLife's consolidated financials for the third quarter of 2025.Total revenue was $23.5 million, an increase of 47% compared to the th

    11/13/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

    SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.* In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP an

    11/12/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FitLife Brands Announces Third Quarter Earnings Call

    OMAHA, NE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the third quarter of fiscal 2025 on Thursday, November 13, 2025. In addition, the Company announced that it will hold an investor conference call after market close on November 13, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 811541.  International participants can dial (973) 528-0163 and provide the same co

    11/7/25 4:00:00 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    $FTLF
    $LFVN
    $OPXS
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FitLife Brands Announces Board Transition

    Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

    4/28/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    Genasys Inc. Appoints New Independent Director

    Genasys Inc. (NASDAQ:GNSS), the global leader in Protective Communications, today announced that pursuant to a recently signed cooperation agreement, R. Rimmy Malhotra ("Rimmy") has been appointed to the Board of Directors, effective January 15, 2025. Mr. Malhotra brings decades of investor and corporate oversight experience. Richard Osgood, Chairman of the Board, said, "We welcome Rimmy to the board. Rimmy's vast experience as a seasoned board advisor will serve us well as we continue to execute on our strategic priorities and enhance value for shareholders. We are confident that his perspectives will add value in the boardroom and in the operational oversight of the company." Richard

    1/16/25 9:00:00 AM ET
    $GNSS
    $HQI
    $OPXS
    Consumer Electronics/Appliances
    Consumer Staples
    Professional Services
    Consumer Discretionary

    $FTLF
    $LFVN
    $OPXS
    Financials

    Live finance-specific insights

    View All

    FitLife Brands Announces Third Quarter 2025 Results

    OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include: On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals ("Irwin"), and Irwin's operating results for the period of August 9 through September 30 are included in FitLife's consolidated financials for the third quarter of 2025.Total revenue was $23.5 million, an increase of 47% compared to the th

    11/13/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    FitLife Brands Announces Third Quarter Earnings Call

    OMAHA, NE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the third quarter of fiscal 2025 on Thursday, November 13, 2025. In addition, the Company announced that it will hold an investor conference call after market close on November 13, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 811541.  International participants can dial (973) 528-0163 and provide the same co

    11/7/25 4:00:00 PM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid December 15, 2025 to all stockholders of record at the close of business on December 1, 2025. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our prod

    11/4/25 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FTLF
    $LFVN
    $OPXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care